Skip to main content
ENANTA PHARMACEUTICALS INC logo

ENANTA PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · ENTA ISIN · US29251M1062 LEI · 529900SSN4DODDQSN594 US Manufacturing
Open in API
Filings indexed 812 across all filing types
Latest filing 2025-05-12 Earnings Release
Country US United States of America
Listing US ENTA

About ENANTA PHARMACEUTICALS INC

https://www.enanta.com/

Enanta Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops small molecule drugs, with a focus on virology and immunology. The company utilizes a robust, chemistry-driven approach to create novel oral therapeutics for diseases with high unmet medical needs. Enanta has a significant track record of success, having developed protease inhibitors that are key components of treatment regimens for chronic hepatitis C virus (HCV) infection, which have cured over one million patients. Its current clinical pipeline is primarily focused on developing treatments for respiratory syncytial virus (RSV) and advancing its immunology programs for inflammatory diseases.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The key section is Item 2.02, which states that the company announced its results for the fiscal quarter ended March 31, 2025, via a press release. The document itself includes the press release as Exhibit 99.1, which reports the financial results for the quarter. The document length is 3138 characters, which is relatively short and primarily serves to announce the earnings results rather than provide a full detailed report. According to the classification rules, an initial announcement of quarterly financial results with key highlights only corresponds to an Earnings Release (ER). The document is not a full interim or quarterly report (IR) because it does not contain comprehensive financial statements or substantive financial data and analysis, only a press release summary. Therefore, the correct classification is Earnings Release (ER).
2025-05-12 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-04-17 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 13, 2025. It reports on the results of stockholder votes at the Annual Meeting, including election of directors, approval of an equity incentive plan amendment, advisory votes on executive compensation, and ratification of the independent auditor. The document contains detailed voting results and descriptions of proposals voted on by shareholders. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA), which includes official results from shareholder votes at any general meeting (AGM or EGM). The document is not an Annual Report, Audit Report, or Proxy Statement, but specifically reports voting outcomes. Therefore, the correct classification is DVA with high confidence.
2025-03-17 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2025-03-14 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2025-03-14 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2025-03-14 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.